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Abstract
Use of radial access for chronic total occlusion (CTO) percutaneous coronary
intervention (PCI) has been increasing. We examined the clinical characteristics and
procedural outcomes of patients who underwent CTO PCI with radial versus femoral
access in the Prospective Global Registry for the Study of CTO Intervention
(PROGRESS‐CTO, NCT02061436). Of 10,954 patients who underwent CTO PCI at
55 centers in 7 countries between 2012 and 2022, 2578 (24%) had a radial only
approach. Patients who underwent radial only access were younger (63 ± 10 vs.
65 ± 10, years, p < 0.001), more likely to be men (84% vs. 81%, p = 0.001), and had
significantly lower prevalence of comorbidities compared with the femoral access
group including diabetes mellitus (39% vs. 45%, p < 0.001) and coronary artery
bypass graft surgery (57% vs. 64%, p < 0.001). In addition, radial only cases had lower
angiographic complexity with lower J‐CTO and PROGRESS‐CTO scores. After
adjusting for potential confounders, radial only access was associated with lower risk
of access site complications (odds ratio [OR]: 0.45, 95% confidence interval [CI]:
0.22–0.91), similar technical success (OR: 0.87, 95% CI: 0.74–1.04) and major
adverse cardiovascular events (MACE) (OR: 0.65, 95% CI: 0.40–1.07), compared
with the femoral access group. Radial only access was used in 24% of CTO PCIs and
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was associated with lower access site complications, and similar technical success
and MACE as compared with the femoral access group.
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| INTRODUCTION
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The study was approved by the institutional review board of
each site.

Complex percutaneous coronary interventions (PCI) have traditionally been performed via femoral access that allows use of large guide
catheters and often provides strong support. Radial access has been
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STATIS TICAL ANALYS I S

increasingly used in complex PCI, such as in chronic total occlusion
(CTO) PCI, with encouraging outcomes.1–5 We examined the

Continuous variables were presented as mean ± standard deviation or

temporal trends, prevalence, and clinical outcomes of radial versus

median (interquartile range) and compared using the independent t

femoral access in CTO PCI in a large multinational CTO PCI registry.

test or Mann–Whitney U test, as appropriate. Categorical variables
were presented as absolute numbers and percentages and were
compared using Chi‐square or Fisher's exact test, as appropriate.

2

| M E TH O D S

Multivariable logistic regression for technical success, MACE, and
vascular access complications was performed separately to adjust for

We examined the Prospective Global Registry for the Study of Chronic

potential confounders using variables with p < 0.10 on univariable

Total Occlusion Intervention (PROGRESS‐CTO, NCT02061436) data-

analysis and clinical plausibility in the multivariable model. Statistical

base after stratifying patients based on access site into 3 groups: radial

analyses were performed using Stata v17.0 (StataCorp).

only, radial/femoral, and femoral only.
PROGRESS‐CTO includes patient level data for CTO PCI
procedures performed between 2012 and 2022 at experienced CTO

4 |

RESULTS

PCI centers from the United States, Canada, Greece, Turkey, Egypt,
Russia, and Lebanon.6 Study data were collected and managed using

4.1 |

Clinical and angiographic characteristics

REDCap (Research Electronic Data Capture) electronic data capture
tools hosted at the Minneapolis Heart Institute Foundation.7,8

Of 10,954 patients that underwent CTO PCI, 2578 (24%) had radial
only access, (12% had single radial access, 12% had biradial access),
29% had femoral‐radial access, 15% had single femoral access, and

2.1

| Definitions

33% had bifemoral access (Figure 1). Compared with the femoral
group, patients who had radial only access were younger, more likely

The radial only group was defined as the absence of femoral access

to be men, and had significantly lower prevalence of comorbidities:

(includes single or biradial access). The radial/femoral (femoral) group

diabetes mellitus, prior heart failure, prior PCI, and/or prior coronary

was defined as access via the right and/or left femoral artery, regardless

artery bypass graft surgery (Table 1). In addition, patients who had

of radial access. The femoral only group was defined as femoral access

radial only access had more favorable angiographic characteristics

without radial access (includes single or bifemoral access).

including lower incidence of proximal cap ambiguity, moderate‐

CTOs were defined according to the definition of CTO Academic

severe proximal tortuosity, moderate‐severe calcification, and signif-

Research Consortium, as absence of antegrade flow through the

icantly lower J‐CTO and PROGRESS‐CTO scores compared with the

lesion with a presumed or documented duration of ≥3 months.9

femoral group (Table 1). Moreover, balloon undilatable or uncrossable

Technical success was defined as the successful canalization of

lesions were more prevalent in the femoral group.

the CTO vessel with <30% residual stenosis and final Thrombolysis in

Ad hoc PCI rates were higher with radial only access (12.2% vs.

Myocardial Infarction (TIMI) 3 flow. Calcification was assessed by

8%, p < 0.001), but equipment use was significantly higher in the

angiography as mild (spots), moderate (involving ≤50% of the

femoral group (Table 1). The CTO vessel was more often the left

reference lesion diameter), or severe (involving ≥50% of the
reference lesion diameter).
The Multicenter CTO Registry of Japan (J‐CTO) score was
calculated as described by Morino et al.,10 the PROGRESS‐CTO score
as described by Christopoulos et al.,11 and the PROGRESS‐CTO
complications score as described by Danek et al.12
Myocardial infarction (MI) was defined using the Third Universal
Definition of Myocardial Infarction.13
In‐hospital major adverse cardiovascular events (MACE) were
defined as the composite of in‐hospital all‐cause mortality, MI, stroke,
urgent repeat revascularization (re‐PCI or surgery), or pericardiocentesis.
Vascular access site complications included small hematoma
(<5 cm), large hematoma (≥5 cm), arteriovenous fistula, pseudoaneurysm, or acute arterial closure.

F I G U R E 1 Distribution of access sites used for CTO PCI in the
PROGRESS‐CTO registry. CTO, chronic total occlusion; PCI,
percutaneous coronary intervention [Color figure can be viewed at
wileyonlinelibrary.com]
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TABLE 1
access site
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Characteristics and procedural outcomes of patients stratified by chronic total occlusion percutaneous coronary intervention

Characteristic/procedural outcomes

Radial only (n = 2578)

Femoral (n = 8376)

p value

Age in years, mean ± SD, (n)

63 ± 10 (n = 2336)

65 ± 10

<0.001

Men, n, (%)

2015 (84)

6115 (81)

0.001

Hypertension, n, (%)

2093 (88)

6701 (90)

0.021

Dyslipidemia, n, (%)

1847 (78)

6685 (89)

<0.001

Atrial fibrillation, n, (%)

214 (11)

668 (13)

0.004

Dyspnea, n, (%)

1519 (66)

4689 (71)

<0.001

Fatigue, n, (%)

1025 (45)

3195 (52)

<0.001

Diabetes mellitus, n, (%)

908 (39)

3289 (45)

<0.001

Peripheral arterial disease, n, (%)

272 (12)

1068 (15)

<0.001

Family history of premature coronary artery disease, n, (%)

694 (32)

1934 (33)

0.371

Prior myocardial infarction, n, (%)

1025 (44)

3134 (45)

0.714

Prior heart failure, n, (%)

601 (26)

2095 (29)

0.003

Prior percutaneous coronary intervention, n, (%)

1368 (57)

4801 (64)

<0.001

Prior coronary artery bypass graft surgery, n, (%)

406 (17)

2546 (33)

<0.001

Left ventricular ejection fraction, mean ± SD, (n)

51 ± 12

50 ± 13

<0.001

Proximal cap ambiguity, n, (%)

668 (27)

2681 (38)

<0.001

Moderate/severe proximal tortuosity, n, (%)

563 (25)

1892 (30)

<0.001

Moderate/severe calcification, n, (%)

891 (35)

3790 (50)

<0.001

CTO length in mm, mean ± SD, (n)

24 ± 17 (2470)

33 ± 22 (7581)

<0.001

J‐CTO score, mean ± SD, (n)

2.0 ± 1.3 (2530)

2.5 ± 1.2 (7859)

<0.001

PROGRESS‐CTO score, mean ± SD, (n)

1.2 ± 1.0 (2281)

1.3 ± 1.0 (6293)

<0.001

PROGRESS‐CTO complications score, mean ± SD, (n)

2.3 ± 1.9 (2215)

3.1 ± 1.9 (5492)

<0.001

Balloon uncrossable, n, (%)

180 (8.2)

645 (10.5)

0.002

Balloon undilatable, n, (%)

116 (5.8)

483 (9.3)

<0.001

LAD

724 (28)

1996 (25)

0.001

LCx

528 (21)

1495 (19)

0.031

RCA

1245 (49)

4288 (54)

<0.001

Left main

3 (0.1)

49 (0.6)

0.002

Ad hoc CTO PCI, n, (%)

289 (12.2)

554 (8)

<0.001

Total number of guidewires, mean ± SD, (n)

4.4 ± 3.2 (2140)

6.1 ± 4.4 (4925)

<0.001

Total number of balloons, mean ± SD, (n)

3.4 ± 2.3 (2123)

4.3 ± 4.2 (4886)

<0.001

Total number of microcatheters, mean ± SD, (n)

1.0 ± 0.9 (2121)

1.6 ± 1.0 (4909)

<0.001

Total number of support catheters, mean ± SD, (n)

0.3 ± 0.5 (1898)

0.5 ± 1.0 (4130)

<0.001

Antegrade wiring

2415 (94)

7107 (85)

<0.001

Retrograde

474 (18)

3009 (36)

<0.001

Procedure time, mean ± SD, (n)

100 ± 57 (2304)

140 ± 82 (6628)

<0.001

CTO target vessel, n, (%)

Crossing strategy, n, (%)

(Continues)
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(Continued)

Characteristic/procedural outcomes

Radial only (n = 2578)

Femoral (n = 8376)

p value

Contrast volume (ml), mean ± SD, (n)

216 ± 114 (2423)

246 ± 127 (7549)

<0.001

AK Fluoroscopy Dose (Gray), mean ± SD, (n)

2.6 ± 2.3 (1535)

2.8 ± 2.1 (5954)

<0.001

Fluoroscopy Time (min), mean ± SD, (n)

42 ± 31 (2418)

54 ± 34 (7525)

<0.001

Technical success, n, (%)

2281 (88.5)

7171 (85.5)

<0.001

Abbreviations: AK, Air kerma; CTO, chronic total occlusion; J‐CTO, Multicenter CTO Registry of Japan; LAD, left anterior descending; LCX, left circumflex;
PCI, percutaneous coronary intervention; PROGRESS‐CTO, Prospective Global Registry for the Study of Chronic Total Occlusion Intervention; RCA, right
coronary artery; SD: Standard deviation.

anterior descending (28% vs. 25%, p = 0.001) or left circumflex (21%
vs. 19%, p = 0.031) in the radial only approach, and less often the
right coronary artery (49% vs. 54%, p < 0.001) or the left main (0.1%
vs. 0.6%, p = 0.002) (Table 1).
Antegrade wiring (94% vs. 85%, p < 0.001) was used more often
in the radial only group, whereas retrograde crossing was used more
often in the femoral group (18% vs. 36%, p < 0.001) (Table 1).
Procedure time, contrast volume, fluoroscopy time and air kerma
fluoroscopy dose were higher in the femoral group (Table 1). In radial
access, access size was either 6F or 7F in over 90% of cases. The
most commonly used guides for antegrade attempts were EBU 3.5
(22%), JR4 (16%), AL 1.0 (13%), AL 0.75 (9%), EBU 3.75 (8%), EBU 4.0
(8%), XB 3.5 (4%), and AL 2.0 (4%); and for retrograde attempts EBU
3.5 (19%), EBU 4.0 (18%), AL 1.0 (14%), JR4 (9%), EBU 3.75 (9%), XB
3.5 (5%), AL 0.75 (4%).
The use of bifemoral access in CTO PCI decreased over time
(from 80% in 2012 to 31% in 2021) and was replaced by

F I G U R E 2 Temporal trends of access site utilization in the
PROGRESS‐CTO registry. CTO, chronic total occlusion [Color figure
can be viewed at wileyonlinelibrary.com]

increasing use of radial access and combined femoral/radial
access (Figure 2).

4.4 |
4.2

Multivariable logistic regression

| Procedural and in‐hospital outcomes
After adjusting for age, sex, dyslipidemia, atrial fibrillation, diabetes

Technical success was significantly higher (88.5% vs. 85.5%,

mellitus, peripheral artery disease, prior heart failure, prior PCI, prior

p < 0.001) (Table 1) and in‐hospital complications including all‐cause

CABG,

mortality (0.2% vs. 0.5%, p = 0.037), MACE (1.5% vs. 2.2%, p = 0.023),

moderate‐severe calcification, and CTO length, radial only access

coronary perforation (3.5% vs. 5.3%, p < 0.001), and vascular access

continued to be associated with lower vascular access complications

complications (0.5% vs. 1.2%, p = 0.001), were all significantly lower

(odds ratio [OR]: 0.45, 95% confidence intervals [CI]: 0.22–0.91,

in the radial only group (Table 2).

p = 0.026) compared with femoral access.

proximal

cap

ambiguity,

moderate‐severe

tortuosity,

After adjusting for the same variables, radial only access was no
longer associated with higher technical success (OR: 0.87, 95% CI:

4.3

| Femoral/radial versus femoral only access

0.74–1.04, p = 0.126) compared with femoral access.
Radial only access continued to have a significant association

Baseline characteristics including demographics, comorbidities, and

with lower MACE (OR: 0.60, 95% CI: 0.37–0.97, p = 0.038) after

angiographic characteristics were comparable between the femoral

adjusting for the same variables; however, when retrograde crossing

only and the femoral group (femoral/radial). Technical success,

strategy was added to the adjustment, radial only access was no

MACE, and vascular access site complications were also similar

longer associated with lower MACE (OR: 0.65, 95% CI: 0.40–1.07,

(Tables 1 and 2).

p = 0.087) compared with femoral access.

SIMSEK
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T A B L E 2 In‐hospital clinical events stratified by chronic total
occlusion percutaneous coronary intervention access site
In‐hospital events

Radial only
(n = 2578)

Femoral
(n = 8376)

p value

All‐cause mortality, n, (%)

5 (0.2)

42 (0.5)

0.037

Major adverse
cardiovascular events,
n, (%)

38 (1.5)

184 (2.2)

0.023

Acute myocardial infarction,
n, (%)

9 (0.4)

57 (0.7)

0.057

Stroke, n, (%)

3 (0.1)

16 (0.2)

0.591

Re‐PCI, n, (%)

6 (0.2)

19 (0.2)

0.956

Emergency coronary artery
bypass graft surgery,
n, (%)

1 (0.04)

9 (0.1)

0.469

Tamponade, n, (%)

21 (0.8)

71 (0.8)

1.0

Pericardiocentesis, n, (%)

21 (0.8)

71 (0.8)

1.0

3 (0.1)

39 (0.5)

0.010

Perforation, n, (%)

90 (3.5)

441 (5.3)

<0.001

Vascular access site
complication, n, (%)

12 (0.5)

103 (1.2)

0.001

Equipment loss, n, (%)

Small hematoma (<5 cm)

7 (0.27)

20 (0.24)

0.769

Large hematoma (≥5 cm)

5 (0.19)

25 (0.30)

0.375

Arteriovenous fistula

0 (0.0)

0 (0.0)

Pseudoaneurysm

0 (0.0)

5 (0.06)

0.598

Acute arterial closure

0 (0.0)

10 (0.12)

0.130

14 (0.5)

60 (0.7)

0.348

Dissection, n, (%)

N/A

Abbreviation: PCI, percutaneous coronary intervention.

5

| DISC US SION

The main findings of our study are that radial only access: (a) is
increasingly being used for CTO PCI, as it was utilized in 24% of all
CTO PCI procedures with increased use over time; (b) is used more
often in lesions with lower angiographic complexity; and (c) is
associated with lower vascular access site complications and similar
technical success and MACE compared with femoral access, after
adjusting for potential confounders (Tables 1 and 2) (Figure 3—
Central Illustration).
Similar to our study, a recent meta‐analysis investigating the
outcomes of radial versus femoral access showed that radial access

F I G U R E 3 (Central illustration): Multiple logistic regression
analyses of technical success, major adverse cardiovascular events,
and vascular access complications [Color figure can be viewed at
wileyonlinelibrary.com]

was used in CTO lesions of lower complexity with J‐CTO score
(2.3 ± 1.2 vs. 2.5 ± 1.3; p < 0.001), with similar technical success

To determine whether the difference in complications were

(78.7% vs. 78.5%, p = 0.24), risk of pericardial tamponade (OR: 0.85,

attributable to femoral access, we created a third comparison group

95% CI: 0.24–3.02, p = 0.8), and rate of emergency CABG (OR: 0.79,

(femoral only), which had similar clinical and angiographic character-

95% CI: 0.29–2.11, p = 0.63), but with significantly lower incidence of

istics and outcomes as the “any femoral” group.

major bleeding (OR: 0.22, 95% CI: 0.10–0.45) and access site
complications (OR: 0.34, 95% CI: 0.22–0.51).14

In the COLOR (Complex Large‐Bore Radial Percutaneous
Coronary Intervention) trial, radial versus femoral access in complex

6
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PCI was compared by randomizing 388 patients with complex lesions

Cardiac Catheterization, NCT04077762) trial, which is randomizing

including LM (14%), CTOs (58%), heavy calcification (19%), or

3266 patients without ST‐segment elevation MI undergoing coronary

bifurcations (9%) to either 7‐French radial (n = 194) or 7‐French

angiogram with possible PCI (non‐CTO) to either radial or state‐of‐

femoral (n = 194) access. While overall procedural success was 86%

the‐art femoral access (18 gauge or 21 gauge, ultrasound‐guided

and 89.2% (p = 0.29) in the femoral and radial arms, respectively,

puncture, routine femoral angiography, and use of closure devices in

procedural success in CTO lesions (n = 223) was 78.9% and 85.3%

femoral access) has the composite primary outcome of BARC type

(p = 0.22) in the femoral and radial groups, respectively.

15

The

primary composite outcome of access‐site related clinically signifi-

2‐3‐5 bleeding at up to 30 days, and will help determine the
comparative effectiveness of radial versus femoral access.

cant bleeding or vascular complications requiring intervention at
discharge was 3.6% for radial and 19.1% for femoral access groups
(p < 0.001), which was driven by less frequent Bleeding Academic

6 |

LIMITATIONS

Research Consortium (BARC) type 2 bleeding (16.5% vs. 3.6% for
femoral vs. radial access) (p < 0.001).15 However, ultrasound guided

Our study has important limitations. First, the PROGRESS‐CTO

puncture was used only in only 40% of femoral and 7% of radial

registry is observational with all inherent limitations. Second, we did

access cases; consistent use of ultrasound‐guided puncture might

not adjust for multiple statistical comparisons, which could lead to

have decreased access site complications.16

false positive findings. Third, events were not adjudicated by an

In the FORT CTO (Femoral or Radial Approach in the Treatment

independent adjudication committee. Fourth, the postprocedure

of Coronary Chronic Total Occlusion) trial, the only dedicated

patency of the radial artery was not routinely assessed. Fifth, the

randomized controlled trial comparing radial versus femoral access

crossover rate from radial to femoral access (or vice versa) was not

in CTO PCI, 610 patients were randomized to radial (n = 305) or

available. Sixth, the PROGRESS‐CTO operators are highly experi-

femoral (n = 305) access.1 In this trial, technical success (88% vs. 89%,

enced in CTO PCI, which could limit the external validity of the study.

p = 0.616) and in‐hospital MACE (2.6% vs. 2.4%) were similar
between the groups; however, the secondary outcome of access
site complications was lower in the radial access group (2.0% vs.

7 |

CONCLUSION

5.6%, p = 0.019).1 No difference was observed in procedure time,
contrast volume, or fluoroscopy time between the groups.1 However,

In a large multinational CTO PCI registry, radial only access was used

in this study access (femoral or radial) was obtained without the use

in 24% of CTO PCIs with increasing use over time, especially in lower

of ultrasound or fluoroscopic guidance, and arterial closure devices

complexity CTOs, and was associated with fewer access site

were not used in the femoral group.17,18 While femoral access might

complications, but similar technical success and MACE compared

provide better equipment support and facilitate CTO PCI, the FORT

with femoral access after adjusting for potential confounders.

CTO trial demonstrated that similarly high success rates can be
achieved in CTO PCI independent of access site, highlighting the
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